Table 1. Participant characteristics at ART stop.
| CHRONIC HIV INFECTION | PHI (SPARTAC) N = 182 | |
| (SMART) N = 1450 | ||
| Sex, female (n, %) | 350 (24%) | 60 (33%) |
| Age, years (median, IQR) | 44 (38, 51) | 34 (28, 42) |
| HIV exposure (n, %) | ||
| Sex between men | 890 (61%) | 114 (63%) |
| Sex between men & women (male) | 222 (15%) | 8 (4%) |
| Sex between men & women (female) | 338 (23%) | 60 (33%) |
| Time since first diagnosed HIV positive, months | 96 (60, 144) | 6 (4, 13) |
| (median, IQR) | ||
| Number of ART drugs, ever (median, IQR) | 5 (4, 7) | 3 (3, 3) |
| Number of ART classes, ever (n, %) | ||
| 1 | 48 (3%) | 0 (0%) |
| 2 | 763 (53%) | 171 (94%) |
| ≥3 | 639 (44%) | 11 (6%) |
| Estimated time on therapy, months (median, IQR) | 72 (48, 96) | 3 (3, 11) |
| ART type at stop (n, %) | ||
| NNRTI based | 674 (46%) | 8 (4%) |
| PI based | 521 (36%) | 171 (94%) |
| 3 NRTI | 132 (9%) | 2 (1%) |
| 3 class | 84 (6%) | 0 (0%) |
| NRTI sparing | 3 (<1%) | 0 (0%) |
| Suboptimal ART | 36 (2%) | 1 (1%) |
| Nadir CD4 count up to ART stop, cells/mm3 | 230 (132, 340) | - |
| (median, IQR; below: n, %) | ||
| <200 | 592 (41%) | - |
| 200–349 | 515 (36%) | - |
| 350–499 | 226 (16%) | - |
| ≥500 | 117 (8%) | - |
| CD4 count at ART stop, cells/mm3 * (median, | 646 (495, 848) | 707 (586, 919) |
| IQR; below: median, IQR by nadir CD4) | ||
| nadir CD4<200 cells/mm3 | 568 (456, 724) | - |
| nadir CD4 200–349 cells/mm3 | 618 (494, 784) | - |
| nadir CD4 350–499 cells/mm3 | 806 (646, 993) | - |
| nadir CD4≥500 cells/mm3 | 948 (784, 1176) | - |
*
Closest up to 24 weeks before ART stop. NB: 2 chronically-infected participants had CD4 count <350 cells/mm3 at ART stop (contrary to SMART inclusion criteria), but both were measured on the day of ART stop and both participants had previous CD4 count >350 cells/mm3 within the previous 6 weeks.